JP2020506946A5 - - Google Patents

Download PDF

Info

Publication number
JP2020506946A5
JP2020506946A5 JP2019542502A JP2019542502A JP2020506946A5 JP 2020506946 A5 JP2020506946 A5 JP 2020506946A5 JP 2019542502 A JP2019542502 A JP 2019542502A JP 2019542502 A JP2019542502 A JP 2019542502A JP 2020506946 A5 JP2020506946 A5 JP 2020506946A5
Authority
JP
Japan
Prior art keywords
oxo
carboxamide
dihydropyridazine
chlorophenyl
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019542502A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020506946A (ja
JP7128826B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/052627 external-priority patent/WO2018146010A1/en
Publication of JP2020506946A publication Critical patent/JP2020506946A/ja
Publication of JP2020506946A5 publication Critical patent/JP2020506946A5/ja
Application granted granted Critical
Publication of JP7128826B2 publication Critical patent/JP7128826B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019542502A 2017-02-09 2018-02-02 がん治療のための2-ヘテロアリール-3-オキソ-2,3-ジヒドロピリダジン-4-カルボキサミド類 Active JP7128826B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17155406.6 2017-02-09
EP17155406 2017-02-09
EP17202882 2017-11-21
EP17202882.1 2017-11-21
PCT/EP2018/052627 WO2018146010A1 (en) 2017-02-09 2018-02-02 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2020506946A JP2020506946A (ja) 2020-03-05
JP2020506946A5 true JP2020506946A5 (enExample) 2021-03-11
JP7128826B2 JP7128826B2 (ja) 2022-08-31

Family

ID=61188789

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019542502A Active JP7128826B2 (ja) 2017-02-09 2018-02-02 がん治療のための2-ヘテロアリール-3-オキソ-2,3-ジヒドロピリダジン-4-カルボキサミド類

Country Status (39)

Country Link
US (2) US12522594B2 (enExample)
EP (1) EP3580211B1 (enExample)
JP (1) JP7128826B2 (enExample)
KR (1) KR102627266B1 (enExample)
CN (3) CN110678459B (enExample)
AU (1) AU2018217860B2 (enExample)
BR (1) BR112019016497A2 (enExample)
CA (1) CA3052718A1 (enExample)
CL (1) CL2019002255A1 (enExample)
CO (1) CO2019008684A2 (enExample)
CR (1) CR20190364A (enExample)
CU (1) CU24564B1 (enExample)
CY (1) CY1124484T1 (enExample)
DK (1) DK3580211T3 (enExample)
DO (1) DOP2019000206A (enExample)
EC (1) ECSP19057713A (enExample)
ES (1) ES2847162T3 (enExample)
GE (2) GEAP202115183A (enExample)
HR (1) HRP20210143T1 (enExample)
HU (1) HUE053191T2 (enExample)
IL (1) IL268469B (enExample)
JO (1) JOP20190193A1 (enExample)
LT (1) LT3580211T (enExample)
MA (1) MA47447B1 (enExample)
MX (1) MX2019009571A (enExample)
MY (1) MY198510A (enExample)
NI (1) NI201900085A (enExample)
PE (1) PE20191496A1 (enExample)
PH (1) PH12019501846A1 (enExample)
PL (1) PL3580211T3 (enExample)
RS (1) RS61401B1 (enExample)
SA (1) SA519402422B1 (enExample)
SG (1) SG11201907232XA (enExample)
SI (1) SI3580211T1 (enExample)
TW (1) TWI770113B (enExample)
UA (1) UA124507C2 (enExample)
UY (1) UY37606A (enExample)
WO (1) WO2018146010A1 (enExample)
ZA (1) ZA201905902B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201892666A1 (ru) * 2016-05-25 2019-08-30 Байер Фарма Акциенгезельшафт 3-оксо-2,6-дифенил-2,3-дигидропиридазин-4-карбоксамиды
JOP20190193A1 (ar) 2017-02-09 2019-08-08 Bayer Pharma AG ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
CN109813913B (zh) * 2019-01-31 2021-11-09 中国医学科学院肿瘤医院 芳烃受体(AhR)在预测免疫治疗效果中的应用
EP3715471A1 (en) * 2019-03-29 2020-09-30 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Ahr signature marker set
EP3721894A1 (en) 2019-04-10 2020-10-14 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Interleukin-4-induced gene 1 (il4i1) as a biomarker and uses thereof
CN112724256B (zh) * 2019-10-28 2022-09-16 中国农业大学 一种高稳定性的磺胺类药物抗体hAb 4D11及其应用
EP3835432A1 (en) 2019-12-10 2021-06-16 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Interleukin-4-induced gene 1 (il4i1) and respective metabolites as biomarkers for cancer
AU2020403801A1 (en) * 2019-12-16 2022-06-02 Bayer Aktiengesellschaft Combination of an AhR-inhibitor and an PD1-inhibitor antibody and its use in the treatment of cancer
EP4110778A1 (en) 2020-02-26 2023-01-04 Jaguahr Therapeutics Pte Ltd Pyridopyrimidine derivatives useful in modulation of ahr signalling
CN115397818A (zh) * 2020-03-27 2022-11-25 东亚St株式会社 氨基嘧啶衍生物及其作为芳烃受体调节剂的应用
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
WO2022078356A1 (zh) * 2020-10-15 2022-04-21 山东轩竹医药科技有限公司 杂芳环类AhR抑制剂
CN114539221A (zh) * 2020-11-27 2022-05-27 苏州泽璟生物制药股份有限公司 氘代2-芳杂环-3-氧-2,3-二氢哒嗪-4-甲酰胺类抑制剂及其制备方法和应用
CN114685426A (zh) * 2020-12-28 2022-07-01 苏州泽璟生物制药股份有限公司 磺酰胺类抑制剂及其制备方法和应用
CN114835687B (zh) * 2021-04-02 2023-09-05 北京华森英诺生物科技有限公司 AhR抑制剂
TW202320777A (zh) * 2021-09-14 2023-06-01 中國大陸商元啟(蘇州)生物製藥股份有限公司 芳基烴受體調節劑及其用於治療疾病及病症之用途
CA3235458A1 (en) 2021-10-20 2023-04-27 University Of Rochester Microrna-mediated methods for rejuvenating cns glial populations
WO2024076300A1 (en) 2022-10-03 2024-04-11 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4134467A1 (de) 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
AU756275B2 (en) 1998-08-14 2003-01-09 Nihon Nohyaku Co., Ltd. Pyridazinone derivatives
JP2000119257A (ja) * 1998-08-14 2000-04-25 Nippon Nohyaku Co Ltd ピリダジノン誘導体
US6358964B1 (en) 2000-07-26 2002-03-19 King Pharmaceuticals Research And Development, Inc. Adenosine, A3 receptor modulators
HU228961B1 (en) 2000-09-18 2013-07-29 Eisai R & D Man Co Triazinones and their use as active ingredients of pharmaceutical compositions
FR2847253B1 (fr) 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
DE102004055998A1 (de) 2004-11-19 2006-05-24 Rheinische Friedrich-Wilhelms-Universität Bonn Niedermolekulare Inhibitoren von Guaninnucleotid-Austauschfaktoren der Cytohesin-Familie
WO2007040565A2 (en) 2004-11-22 2007-04-12 King Pharmaceuticals Research & Development, Inc. Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists
WO2006082952A1 (ja) 2005-02-01 2006-08-10 Takeda Pharmaceutical Company Limited アミド化合物
US20060178388A1 (en) 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
AR057986A1 (es) 2005-11-21 2008-01-09 Japan Tobacco Inc Compuesto heterociclico y su uso farmaceutico
ES2421191T3 (es) 2006-05-03 2013-08-29 Symrise Ag Antagonistas del receptor de Ah
GB0614579D0 (en) 2006-07-21 2006-08-30 Black James Foundation Pyrimidine derivatives
DE102006054205A1 (de) 2006-11-15 2008-05-29 Rheinische Friedrich-Wilhelms Universität Verwendung von Cytohesin-Inhibitoren zur chemischen Induktion von Langlebigkeit
WO2008080056A2 (en) * 2006-12-21 2008-07-03 Sloan-Kettering Institute For Cancer Research Pyridazinones and furan-containing compounds
KR101178319B1 (ko) 2007-11-29 2012-09-07 액테리온 파마슈티칼 리미티드 포스폰산 유도체 및 p2y12 수용체 길항물질로서 이들의 용도
EP2328586A2 (en) 2008-05-20 2011-06-08 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
CN102271682B (zh) 2008-10-31 2015-12-16 默沙东公司 用于治疗疼痛的p2x3受体拮抗剂
US20130338201A1 (en) 2009-11-02 2013-12-19 Ahr Pharmaceuticals, Inc. Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester
CN103179968B (zh) 2010-07-27 2017-10-03 波士顿大学管理委员会 作为癌症疗法的芳烃受体(AhR)调节剂
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
WO2015143164A1 (en) 2014-03-19 2015-09-24 President And Fellows Of Harvard College Antimicrobial agents and screening methods
EA201892666A1 (ru) * 2016-05-25 2019-08-30 Байер Фарма Акциенгезельшафт 3-оксо-2,6-дифенил-2,3-дигидропиридазин-4-карбоксамиды
JOP20190193A1 (ar) 2017-02-09 2019-08-08 Bayer Pharma AG ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
EP3707138B1 (en) 2017-11-06 2022-07-13 Bristol-Myers Squibb Company Isofuranone compounds useful as hpk1 inhibitors
US11459312B2 (en) 2017-11-21 2022-10-04 Bayer Aktiengesellschaft Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides
CA3082857A1 (en) 2017-11-21 2019-05-31 Bayer Aktiengesellschaft 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides
WO2019101641A1 (en) 2017-11-21 2019-05-31 Bayer Aktiengesellschaft 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor anatgonists
US11524944B2 (en) 2017-11-21 2022-12-13 Bayer Aktiengesellschaft 2-phenylpyrimidine-4-carboxamides as AHR inhibitors
JP7486478B2 (ja) 2018-09-19 2024-05-17 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト スピロ環状2,3-ジヒドロ-7-アザインドール化合物およびその使用
WO2020102506A1 (en) 2018-11-14 2020-05-22 The Broad Institute, Inc. Aryl hydrocarbon receptor (ahr) activator compounds as cancer therapeutics
JOP20220034A1 (ar) 2019-08-12 2023-01-30 Bayer Ag مركبات [1، 2، 4] تريازولو [1، 5-جـ] كوينازولين-5-أمين
WO2021074279A1 (en) 2019-10-16 2021-04-22 Bayer Aktiengesellschaft Spiro-fused tricyclic map4k1 inhibitors
WO2021249913A1 (en) 2020-06-09 2021-12-16 Bayer Aktiengesellschaft 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer
WO2022167627A1 (en) 2021-02-05 2022-08-11 Bayer Aktiengesellschaft Map4k1 inhibitors

Similar Documents

Publication Publication Date Title
JP2020506946A5 (enExample)
HRP20210143T1 (hr) 2-heteroaril-3-okso-2,3-dihidropiridazin-4-karboksamidi za liječenje raka
RU2404164C2 (ru) Производные пиридин-3-карбоксамида в качестве обратных агонистов св1
RU2454405C2 (ru) Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина
RU2497822C2 (ru) Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний
RU2485114C2 (ru) Карбоксамидные соединения и их применение в качестве ингибиторов кальпаинов
JP2017530185A5 (enExample)
JP2019537571A5 (enExample)
JP2019533694A5 (enExample)
JP2019518036A5 (enExample)
JP2016534023A5 (enExample)
JP2016528201A5 (enExample)
RU2018104868A (ru) 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1
JP2021502387A5 (enExample)
RU2014147191A (ru) Амидопроизводные как блокаторы ttx-s
JP2010539110A5 (enExample)
JP2017511794A5 (enExample)
JP2017537948A5 (enExample)
RU2019133530A (ru) ПРОИЗВОДНЫЕ АМИДА В КАЧЕСТВЕ БЛОКАТОРОВ Nav1.7 И Nav1.8
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
RU2018131775A (ru) 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета
JP2018505876A5 (enExample)
JP2020502058A5 (enExample)
JP2018522847A5 (enExample)
JP2019532072A5 (enExample)